Skip to main content

A phase 2, multicentre, open-label, single arm study to evaluate theeffectiveness and safety of rezafungin (as acetate) in the treatment of chronic pulmonaryaspergillosis (CPA) in patients with limited treatment options.

Open
  • Protocol code: MR907-2502
  • EudraCT code: No aplica
  • Research group: Infectious Diseases
  • Service: Infectious
  • Principal investigator:  Len Abad, Oscar
  • Pathology: Certes malalties infeccioses i parasitàries
  • Phase: Fase II